New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England

In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to...
Read More
No matter how you look at it, the Most Favored Nation rule is bad policy

Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access...
Read More
Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D

Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...
Read More
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More
Executive order threatens R&D when we need it most to fight COVID-19

In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
The continued imperative to protect U.S. innovation worldwide

The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...
Read More
Three reasons the Administration should abandon its International Pricing Index proposal

According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American...
Read More
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Setting the record straight on international reference pricing

There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
By the numbers: A look at the Part B International Pricing Index Model

Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...
Read More